FTC, Four States Sue WPATH Over Claims On Youth Gender Treatments
The Federal Trade Commission and the states of Alaska, Iowa, Nebraska and Texas sued the World Professional Association for Transgender Health on Wednesday, June 17, 2026, accusing it of misleading parents about youth gender treatments.[1]
The complaint says WPATH made deceptive claims about puberty blockers, cross-sex hormones and surgeries for minors and removed age-based recommendations from its standards of care.[1] FTC Chair Andrew Ferguson framed the case as protecting parents from deception, while WPATH called the action retaliatory and said its standards support individualized treatment.[1]
On January 15, 2026, the FTC issued a Civil Investigative Demand to WPATH as part of an inquiry into whether the group had made or aided false or unsubstantiated claims about treatments for minors. WPATH petitioned to quash the demand on February 9 and filed suit in D.C. federal court on February 18 to block enforcement on First Amendment and jurisdiction grounds. A federal judge granted WPATH a preliminary injunction on May 7 that temporarily halted the agency's inquiry.
The FTC had hosted a July 9, 2025 workshop examining potential deceptive trade practices in gender-affirming care for minors. Analysis of private insurance claims from 2018 to 2022 found 926 adolescents received puberty blockers and 1,927 received cross-sex hormones among more than 5.1 million adolescents ages 8-17. The case has drawn sharp social-media reactions, with supporters praising the suit as accountability and critics calling it retaliatory.
The mainstream summary does not address the broader implications of the lawsuit, particularly the chilling effect that legal actions like this can have on open discussions about youth gender-affirming care. Steve Stewart-Williams argues that cultural and political pressures have made it socially risky to engage in evidence-based discussions about sex differences, which could undermine scientific and policy debates. He emphasizes the need for nuanced clinical judgment rather than ideological policing, a perspective that is absent from the mainstream framing of the FTC's actions as purely protective of parents. This omission suggests a lack of acknowledgment regarding the complexities surrounding the discourse on gender treatments for minors.
Additionally, while the mainstream summary cites the number of adolescents receiving puberty blockers and cross-sex hormones, it does not mention the significant concerns raised by various studies regarding the efficacy and safety of these treatments. The 2024 Cass Review highlighted that the evidence base for such interventions is of very low certainty, leading to policy shifts in multiple countries. This context is crucial for understanding the motivations behind the FTC's lawsuit and the broader debate on youth gender care, which the mainstream account underrepresents.[2]
Show source details & analysis (1 source)
📊 Relevant Data
A JAMA Pediatrics analysis of U.S. private insurance claims data covering more than 5.1 million adolescents ages 8-17 found that 926 received puberty blockers and 1,927 received cross-sex hormones between 2018 and 2022.
Gender-Affirming Medications Among Transgender and Gender-Diverse Adolescents — JAMA Pediatrics
📌 Key Facts
- On Wednesday, June 17, 2026, the FTC and the states of Alaska, Iowa, Nebraska and Texas filed a lawsuit against WPATH.
- The complaint alleges WPATH made deceptive claims about puberty blockers, cross-sex hormones and surgeries for minors and removed age-based recommendations from its standards of care.
- FTC Chair Andrew Ferguson publicly framed the case as protecting parents from deception, while WPATH called the action retaliatory and said its standards support individualized treatment.
📊 Analysis & Commentary (2)
"The piece — an opinion commentary linked to the FTC suit against WPATH — argues that litigation, political pressure, and social taboos are choking off honest, nuanced discussion of biological sex differences and the difficult empirical and ethical tradeoffs in youth gender care; the author endorses open, evidence‑based debate (with careful distinctions between averages and individuals) and critiques censorious or politicized responses that produce a chilling effect."
"A City Journal opinion piece skeptical of claims that anti‑LGBTQ+ laws causally worsen transgender teens' mental health; the author critiques the quality of the evidence activists cite, argues correlation ≠ causation, and urges stricter evidentiary standards and policy caution — commentary aimed at the debate over youth gender‑affirming care such as that at the center of the FTC and state actions against WPATH."
📰 Source Timeline (1)
Follow how coverage of this story developed over time